Search

Your search keyword '"Crossley, B."' showing total 364 results
Start Over Author "Crossley, B."
364 results on '"Crossley, B."'

2. Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey

Author

Spinou, A., primary, Almagro, M., additional, Harris, B., additional, Boyd, J., additional, Berg, T., additional, Herrero-Cortina, B., additional, Posthumous, A., additional, Aliberti, S., additional, Crossley, B., additional, Ruddy, T.F., additional, Stein, N., additional, Crichton, M.L., additional, Goeminne, P.C., additional, Chalmers, J.D., additional, and Shteinberg, M., additional

Published
2024
Full Text
View/download PDF

3. Genotypic Characterization of Emerging Avian Reovirus Genetic Variants in California.

Author

Egaña-Labrin, S, Hauck, R, Figueroa, A, Stoute, S, Shivaprasad, HL, Crispo, M, Corsiglia, C, Zhou, H, Kern, C, Crossley, B, and Gallardo, RA

Subjects
Infectious Diseases, Infection, Biochemistry and Cell Biology, Other Physical Sciences
Abstract

This study focuses on virus isolation of avian reoviruses from a tenosynovitis outbreak between September 2015 and June 2018, the molecular characterization of selected isolates based on partial S1 gene sequences, and the full genome characterization of seven isolates. A total of 265 reoviruses were detected and isolated, 83.3% from tendons and joints, 12.3% from the heart and 3.7% from intestines. Eighty five out of the 150 (56.6%) selected viruses for sequencing and characterization were successfully detected, amplified and sequenced. The characterized reoviruses grouped in six distinct genotypic clusters (GC1 to GC6). The most represented clusters were GC1 (51.8%) and GC6 (24.7%), followed by GC2 (12.9%) and GC4 (7.2%), and less frequent GC5 (2.4%) and GC3 (1.2%). A shift on cluster representation throughout time occurred. A reduction of GC1 and an increase of GC6 classified strains was noticed. The highest homologies to S1133 reovirus strain were detected in GC1 (~77%) while GC2 to GC6 homologies ranged between 58.5 and 54.1%. Over time these homologies have been maintained. Seven selected isolates were full genome sequenced. Results indicated that the L3, S1 and M2 genes, coding for proteins located in the virus capsid accounted for most of the variability of these viruses. The information generated in the present study helps the understanding of the epidemiology of reoviruses in California. In addition, provides insights on how other genes that are not commonly studied add variability to the reovirus genome.

Published
2019

4. Bovine herpes virus type-4 infection among postpartum dairy cows in California: risk factors and phylogenetic analysis

Author

Areda, D, Chigerwe, M, and Crossley, B

Subjects
Agricultural, Veterinary and Food Sciences, Medical Microbiology, Biomedical and Clinical Sciences, Infectious Diseases, Genetics, Aetiology, 2.2 Factors relating to the physical environment, Infection, Animals, California, Cattle, Cattle Diseases, Cross-Sectional Studies, Female, Genome, Viral, Genotype, Herpesviridae Infections, Herpesvirus 4, Bovine, Phylogeny, Postpartum Period, Prevalence, Risk Factors, Tumor Virus Infections, Bovine herpes virus type 4, dairy cows, phylogenetic analysis, prevalence, Public Health and Health Services, Epidemiology, Veterinary sciences, Clinical sciences
Abstract

The aims of this study were to determine the prevalence and associated risk factors of bovine herpes virus type-4 (BoHV-4) infection and describe the genetic characteristics and predominant genotypes of the virus in Yolo and Tulare counties, California. A cross-sectional study involving multi-stage sampling technique was used. One hundred and forty-eight post-partum cows were enrolled from 11 dairy farms. Uterine/vaginal samples were collected and tested for BoHV-4 and other co-infecting viruses using real-time PCR. Data were analysed using multilevel logistic mixed-effect model. Phylogenetic analysis of 10 BoHV-4 isolates was conducted by targeting three open reading frames (ORF3, ORF8 and ORF 22) of the viral genome. The prevalence of BoHV-4 infection was 22.3% (33/148), while post-partum metritis was 33.8% (48/142). Strong association was found between BoHV-4 infection and lactation number, lactation stage and post-partum metritis. The odds of being positive for BoHV-4 infection were 6.47 times (95% CI 1.17-35.92; P 240 days). Cows with post-partum metritis were 4.51 times (95% CI 1.27-16.02; P < 0.05) more likely to test positive for BoHV-4 infection compared with those without post-partum metritis. Phylogenetic analysis of BoHV-4 based on sequencing of glycoprotein and thymidine kinase (TK) genes revealed genetic variability of the virus with glycoprotein B genotype 1 and TK genotype 2 as being dominant genotypes. The reported high genetic variability of BoHV-4 indicates the possibility of co-infection with multiple genotypes.

Published
2018

5. Agreement Among 4 Sampling Methods to Identify Respiratory Pathogens in Dairy Calves with Acute Bovine Respiratory Disease.

Author

Doyle, D, Credille, B, Lehenbauer, TW, Berghaus, R, Aly, SS, Champagne, J, Blanchard, P, Crossley, B, Berghaus, L, Cochran, S, and Woolums, A

Subjects
Nasal Mucosa, Nasopharynx, Trachea, Animals, Cattle, Mycoplasma bovis, Respiratory Syncytial Virus, Bovine, Coronavirus, Respiratory Tract Infections, Cattle Diseases, Acute Disease, Bronchoalveolar Lavage, Female, Bacteria, Diagnosis, Pneumonia, Virus, Lung, Biotechnology, Infection, Veterinary Sciences
Abstract

BackgroundFour sampling techniques commonly are used for antemortem identification of pathogens from cattle with bovine respiratory disease (BRD): the nasal swab (NS), guarded nasopharyngeal swab (NPS), bronchoalveolar lavage (BAL), and transtracheal wash (TTW). Agreement among these methods has not been well characterized.ObjectiveTo evaluate agreement among TTW and NS, NPS, or BAL for identification of viral and bacterial pathogens in dairy calves with BRD.AnimalsOne hundred dairy calves with naturally acquired BRD.MethodsCalves were sampled by all 4 methods. Viral agents were identified by real-time RT-PCR, bacteria were identified by aerobic culture, and Mycoplasma bovis (M. bovis) isolates were speciated by PCR. Agreement among TTW and NS, NPS, or BAL was evaluated by calculating the kappa statistic and percent positive agreement. McNemar's exact test was used to compare the proportions of positive results.ResultsAgreement among TTW and NS, TTW and NPS, and TTW and BAL, was very good for identification of P. multocida, M. haemolytica, and M. bovis. For bovine respiratory syncytial virus (BRSV), agreement with TTW was moderate for NS, good for NPS, and very good for BAL. For bovine coronavirus (BCV), agreement with TTW was moderate for NS and NPS, and good for BAL. McNemar's test was significant only for BCV, indicating that for this pathogen the proportion of positive results from NS and NPS could not be considered comparable to TTW.Conclusions and clinical importanceThis study provides guidance for veterinarians selecting diagnostic tests for antemortem identification of pathogens associated with BRD.

Published
2017

7. The sensitivity and specificity of hyperglycosylated hCG (hhCG) levels to reliably diagnose clinical IVF pregnancies at 6 days following embryo transfer

Author

Cedars, Marcelle, Strom, CM, Bonilla-Guererro, R, Zhang, K, Doody, KJ, Tourgeman, D, Alvero, R, Cedars, MI, Crossley, B, Pandian, R, and Sharma, R

Abstract

Objective To determine the sensitivity and specificity of hyperglycosylated hCG (hhCG) measurements for the diagnosis of clinical pregnancies in the IVF setting and how soon post embryo transfer (ET) a pregnancy can be detected using an ultrasensitive (hhC

Published
2012

10. Armored RNA as virus surrogate in a real-time reverse transcriptase PCR assay proficiency panel

Author

Hietala, S K and Crossley, B M

Abstract

In recent years testing responsibilities for high-consequence pathogens have been expanded from national reference laboratories into networks of local and regional laboratories in order to support enhanced disease surveillance and to test for surge capacity. This movement of testing of select agents and high-con sequence pathogens beyond reference laboratories introduces a critical need for standardized, noninfectious surrogates of disease agents for use as training and proficiency test samples. In this study, reverse transcription-PCR assay RNA targets were developed and packaged as armored RNA for use as a noninfectious, quantifiable synthetic substitute for four high-consequence animal pathogens: classical swine fever virus; foot-and-mouth disease virus; vesicular stomatitis virus, New Jersey serogroup; and vesicular stomatitis virus, Indiana serogroup. Armored RNA spiked into oral swab fluid specimens mimicked virus-positive clinical material through all stages of the reverse transcription-PCR testing process, including RNA recovery by four different commercial extraction procedures, reverse transcription, PCR amplification, and real-time detection at target concentrations consistent with the dynamic ranges of the existing real-time PCR assays. The armored RNA concentrations spiked into the oral swab fluid specimens were stable under storage conditions selected to approximate the extremes of time and temperature expected for shipping and handling of proficiency panel samples, including 24 h at 37 degrees C and 2 weeks at temperatures ranging from ambient room temperature to -70 degrees C. The analytic test performance, including the reproducibility over the dynamic range of the assays, indicates that armored RNA can provide a noninfectious, quantifiable, and stable virus surrogate for specific assay training and proficiency test purposes.

Published
2006

12. Pathogen detection and disease diagnosis in wildlife: challenges and opportunities

Author

Michel, A.L., van Heerden, H., Prasse, D., Rutten, Victor, Al Dahouk, B.M, Crossley, B. M., Immunologie, and dI&I RA-I&I I&I

Subjects
Medicine(all), Infectious disease, Zoonosis, Emerging disease, Test validation, Novel diagnostic approach, Pathogen detection, Diagnostic test, Wildlife
Abstract

Recent decades have witnessed an increase in the demand for pathogen detection and other diagnostic approaches for wild animal populations as interest has grown in infectious diseases that occur in wildlife. This is partially as a result of human population encroachment into wildlife habitats, efforts to protect vulnerable wildlife populations and an increased commercial use of wildlife. As contact rates increase, so does the spillover risk of pathogens between wildlife, domestic animals and humans. The challenges encountered when developing and validating diagnostic tests for use in wildlife are manifold and primarily centre on issues concerning diagnostic samples and suitable test approaches. Under these constraints, it is tempting to resolve the situation by adopting diagnostic tests validated for domestic animal species. Numerous examples using this approach have been published in the literature and some are presented in this paper. The authors present scenarios highlighting advantages and disadvantages of different types of tests in wildlife and current impediments to their validation. Special attention is drawn to future perspectives with regard to the potential of novel and innovative technologies to improve detection of existing, and discovery of unknown, pathogens as well as to accelerate our understanding of infectious wildlife diseases and their diagnosis.

Published
2021

17. Pathogen detection and disease diagnosis in wildlife: challenges and opportunities,Detección de patógenos y diagnóstico de enfermedades en la fauna silvestre: dificultades y oportunidades,Détection des agents pathogènes et diagnostic des maladies dans la faune sauvage: difficultés et perspectives: challenges and opportunities

Author

Michel, A.L., van Heerden, H., Prasse, D., Rutten, Victor, Al Dahouk, B.M, Crossley, B. M., Michel, A.L., van Heerden, H., Prasse, D., Rutten, Victor, Al Dahouk, B.M, and Crossley, B. M.

Abstract

Recent decades have witnessed an increase in the demand for pathogen detection and other diagnostic approaches for wild animal populations as interest has grown in infectious diseases that occur in wildlife. This is partially as a result of human population encroachment into wildlife habitats, efforts to protect vulnerable wildlife populations and an increased commercial use of wildlife. As contact rates increase, so does the spillover risk of pathogens between wildlife, domestic animals and humans. The challenges encountered when developing and validating diagnostic tests for use in wildlife are manifold and primarily centre on issues concerning diagnostic samples and suitable test approaches. Under these constraints, it is tempting to resolve the situation by adopting diagnostic tests validated for domestic animal species. Numerous examples using this approach have been published in the literature and some are presented in this paper. The authors present scenarios highlighting advantages and disadvantages of different types of tests in wildlife and current impediments to their validation. Special attention is drawn to future perspectives with regard to the potential of novel and innovative technologies to improve detection of existing, and discovery of unknown, pathogens as well as to accelerate our understanding of infectious wildlife diseases and their diagnosis.

Published
2021

22. A Community-Based Intervention to Improve Health-Related Quality of Life in Children of Parents with Serious Mental Illness: Feasibility Study

Author

Abel, Kathryn M, Bee, Penny, Gega, Lina, Gellatly, Judith, Kolade, Adekeye, Hunter, D., Callender, C, Carter, Lesley-Anne, Meacock, Rachel, Bower, Peter, Stanley, N, Calam, R, Wolpert, Miranda, Stewart, Pete, Emsley, Richard, Holt, K, Linklater, H, Douglas, S, Stokes-Crossley, B, and Green, J A

Subjects
B900, M900, L900, L400
Abstract

Background\ud Quality of life for children and adolescents living with serious parental mental illness can be impaired, but evidence-based interventions to improve it are scarce.\ud \ud Objective\ud Co-production of a child-centred intervention [called Young Simplifying Mental Illness plus Life Enhancement Skills (SMILES)] to improve the health-related quality of life of children and adolescents living with serious parental mental illness, and evaluating its acceptability and feasibility for delivery in NHS and community settings.\ud \ud Design\ud Qualitative and co-production methods informed the development of the intervention (Phase I). A feasibility randomised controlled trial was designed to compare Young SMILES with treatment as usual (Phase II). Semistructured qualitative interviews were used to explore acceptability among children and adolescents living with their parents, who had serious mental illness, and their parents. A mixture of semistructured qualitative interviews and focus group research was used to examine feasibility among Young SMILES facilitators and referrers/non-referrers.\ud \ud Setting\ud Randomisation was conducted after baseline measures were collected by the study co-ordinator, ensuring that the blinding of the statistician and research team was maintained to reduce detection bias.\ud \ud Participants\ud Phase I: 14 children and adolescents living with serious parental mental illness, seven parents and 31 practitioners from social, educational and health-related sectors. Phase II: 40 children and adolescents living with serious parental mental illness, 33 parents, five referrers/non-referrers and 16 Young SMILES facilitators.\ud \ud Intervention\ud Young SMILES was delivered at two sites: (1) Warrington, supported by the National Society for the Prevention of Cruelty to Children (NSPCC), and (2) Newcastle, supported by the NHS and Barnardo’s. An eight-session weekly group programme was delivered, with four to six children and adolescents living with serious parental mental illness per age-appropriate group (6–11 and 12–16 years). At week 4, a five-session parallel weekly programme was offered to the parents/carers. Sessions lasted 2 hours each and focused on improving mental health literacy, child–parent communication and children’s problem-solving skills.\ud \ud Main outcome measures\ud Phase ll children and parents completed questionnaires at randomisation and then again at 4 and 6 months post randomisation. Quality of life was self-reported by children and proxy-reported by parents using the Paediatric Quality of Life questionnaire and KIDSCREEN. Semistructured interviews with parents (n = 14) and children (n = 17) who participated in the Young SMILES groups gathered information about their motivation to sign up to the study, their experiences of participating in the group sessions, and their perceived changes in themselves and their family members following intervention. Further interviews with individual referrers (n = 5) gathered information about challenges to recruitment and randomisation. Two focus groups (n = 16) with practitioners who facilitated the intervention explored their views of the format and content of the Young SMILES manual and their suggestions for changes.\ud \ud Results\ud A total of 35 families were recruited: 20 were randomly allocated to Young SMILES group and 15 to treatment as usual. Of those, 28 families [15/20 (75%) in the intervention group and 13/15 (87%) in the control group] gave follow-up data at the primary end point (4 months post baseline). Participating children had high adherence to the intervention and high completion rates of the questionnaires. Children and adolescents living with their parents, who had serious mental illness, and their parents were mainly very positive and enthusiastic about Young SMILES, both of whom invoked the benefits of peer support and insight into parental difficulties. Although facilitators regarded Young SMILES as a meaningful and distinctive intervention having great potential, referrers identified several barriers to referring families to the study. One harm was reported by a parent, which was dealt with by the research team and the NSPCC in accordance with the standard operating procedures.\ud \ud Limitations\ud The findings from our feasibility study are not sufficient to recommend a fully powered trial of Young SMILES in the near future. Although it was feasible to randomise children and adolescents living with serious parental mental illness of different ages to standardised, time-limited groups in both NHS and non-NHS settings, an intervention like Young SMILES is unlikely to address underlying core components of the vulnerability that children and adolescents living with serious parental mental illness express as a population over time.\ud \ud Conclusions\ud Young SMILES was widely valued as unique in filling a recognised gap in need. Outcome measures in future studies of interventions for children and adolescents living with serious parental mental illness are more likely to capture change in individual risk factors for reduced quality of life by considering their unmet need, rather than on an aggregate construct of health-related quality of life overall, which may not reflect these young people’s needs.\ud \ud Future work\ud A public health approach to intervention might be best. Most children and adolescents living with serious parental mental illness remain well most of the time, so, although their absolute risks are low across outcomes (and most will remain resilient most of the time), consistent population estimates find their relative risk to be high compared with unexposed children. A public health approach to intervention needs to be both tailored to the particular needs of children and adolescents living with serious parental mental illness and agile to these needs so that it can respond to fluctuations over time.\ud \ud Trial registration\ud Current Controlled Trials ISRCTN36865046.

Published
2020

25. Predictors of outcome of mammography in the National Health Service Breast Screening Programme. (Original Paper)

Author

Banks, E., Reeves, G., Beral, V., Bull, D., Crossley, B., Simmonds, M., Hilton, E., Bailey, S., Barrett, N., Briers, P., English, R., Jackson, A., Kutt, E., Lavelle, J., Rockall, L., Wallis, M.G., and Wilson, M.

Subjects
Medical tests -- Usage, Mammography -- Evaluation -- Usage, Breast cancer -- Diagnosis, Health, Social sciences
Abstract

Background: Little is known about the Factors influencing the risk of recall for assessment, invasive diagnostic procedures, and early rescreening after screening mammography. Methods: From June 1996 to March 1 [...]

Published
2002

26. Allocating external financing for health: a discrete choice experiment of stakeholder preferences

Author

Grépin, Karen A.; Pinkstaff, Crossley B.; Hole, Arne Risa; Henderson, Klara; Norheim, Ole Frithjof; Røttingen, John-Arne; Ottersen, Trygve, http://orcid.org/0000-0003-0060-6451 Pinkstaff, Crossley, Grépin, Karen A.; Pinkstaff, Crossley B.; Hole, Arne Risa; Henderson, Klara; Norheim, Ole Frithjof; Røttingen, John-Arne; Ottersen, Trygve, and http://orcid.org/0000-0003-0060-6451 Pinkstaff, Crossley

Abstract

PR, IFPRI3; ISI; CRP4, PHND; A4NH, CGIAR Research Program on Agriculture for Nutrition and Health (A4NH), Most donors of external financing for health use allocation policies to determine which countries are eligible to receive financial support and how much support each should receive. Currently, most of these policies place a great deal of weight on income per capita as a determinant of aid allocation but there is increasing interest in putting more weight on other country characteristics in the design of such policies. It is unclear, however, how much weight should be placed on other country characteristics. Using an online discrete choice experiment designed to elicit preferences over country characteristics to guide decisions about the allocation of external financing for health, we find that stakeholders assign a great deal of importance to health inequalities and the burden of disease but put very little weight on income per capita. We also find considerable variation in preferences across stakeholders, with people from low- and middle-income countries putting more weight on the burden of disease and people from high-income countries putting more weight on health inequalities

Published
2018

29. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies

Author

Gaitskell, K, Hermon, C, Moser, K, Reeves, G, Peto, R, Brinton, L, Marchbanks, P, Negri, E, Ness, R, Peeters, PHM, Vessey, M, Calle, EE, Gapstur, SM, Patel, AV, Dal Maso, L, Talamini, R, Chetrit, A, Hirsh-Yechezkel, G, Lubin, F, Sadetzki, S, Banks, E, Beral, V, Bull, D, Callaghan, K, Crossley, B, Goodill, A, Green, J, Key, T, Sitas, F, Collins, R, Doll, R, Gonzalez, A, Lee, N, Ory, HW, Peterson, HB, Wingo, PA, Martin, N, Pardthaisong, T, Silpisornkosol, S, Theetranont, C, Boosiri, B, Chutivongse, S, Jimakorn, P, Virutamasen, P, Wongsrichanalai, C, Tjonneland, A, Titus-Ernstoff, L, Byers, T, Rohan, T, Mosgaard, BJ, Yeates, D, Freudenheim, JL, Chang-Claude, J, Kaaks, R, Anderson, KE, Folsom, A, Robien, K, Hampton, J, Newcomb, PA, Rossing, MA, Thomas, DB, Weiss, NS, Riboli, E, Clavel-Chapelon, F, Cramer, D, Hankinson, SE, Tworoger, SS, Franceschi, S, La Vecchia, C, Adami, HO, Magnusson, C, Riman, T, Weiderpass, Elisabete, Wolk, A, Schouten, LJ, van den Brandt, PA, Chantarakul, N, Koetsawang, S, Rachawat, D, Palli, D, Black, A, Brinton, LA, Freedman, DM, Hartge, P, Hsing, AW, Lacey, JV, Hoover, RN, Schairer, C, Urban, M, Graff-Iversen, Sidsel, Selmer, Randi, Bain, CJ, Green, AC, Purdie, DM, Siskind, V, Webb, PM, Moysich, K, McCann, SE, Hannaford, P, Kay, C, Binns, CW, Lee, AH, Zhang, M, Ness, RB, Nasca, P, Coogan, PF, Palmer, JR, Rosenberg, L, Kelsey, J, Paffenbarger, R, Whittemore, A, Katsouyanni, K, Trichopoulou, A, Trichopoulos, D, Tzonou, A, Dabancens, A, Martinez, L, Molina, R, Salas, O, Goodman, MT, Lurie, G, Carney, ME, Wilkens, LR, Hartman, L, Manjer, J, Olsson, H, Grisso, JA, Morgan, M, Wheeler, JE, Bunker, CH, Edwards, RP, Modugno, F, Casagrande, J, Pike, MC, Ross, RK, Wu, AH, Miller, AB, Kumle, Merethe, Gram, Inger Torhild, Lund, Eiliv, McGowan, L, Shu, XO, Zheng, W, Farley, TMM, Holck, S, Meirik, O, Risch, HA, E. E. Calle, S. M. Gapstur, A. V. Patel, L. Dal Maso, R. Talamini, A. Chetrit, G. Hirsh Yechezkel, F. Lubin, S. Sadetzki, E. Bank, V. Beral, D. Bull, K. Callaghan, B. Crossley, K. Gaitskell, A. Goodill, J. Green, C. Hermon, T. Key, K. Moser, G. Reeve, F. Sita, R. Collin, R. Doll, R. Peto, C. A. Gonzalez, N. Lee, P. Marchbank, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, A. Tjonneland, L. Titus Ernstoff, T. Byer, T. Rohan, B. J. Mosgaard, M. Vessey, D. Yeate, J. L. Freudenheim, J. Chang Claude, R. Kaak, K. E. Anderson, A. Folsom, K. Robien, J. Hampton, P. A. Newcomb, M. A. Rossing, D. B. Thoma, N. S. Wei, E. Riboli, F. Clavel Chapelon, D. Cramer, S. E. Hankinson, S. S. Tworoger, S. Franceschi, C. La Vecchia, E. Negri, H. O. Adami, C. Magnusson, T. Riman, E. Weiderpa, A. Wolk, L. J. Schouten, P. A. van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, D. Palli, A. Black, L. A. Brinton, D. M. Freedman, P. Hartge, A. W. Hsing, J. Lacey, R. N. Hoover, C. Schairer, M. Urban, S. Graff Iversen, R. Selmer, C. J. Bain, A. C. Green, D. M. Purdie, V. Siskind, P. M. Webb, K. Moysich, S. E. Mccann, P. Hannaford, C. Kay, C. W. Binn, A. H. Lee, M. Zhang, R. B. Ne, P. Nasca, P. F. Coogan, J. R. Palmer, L. Rosenberg, J. Kelsey, R. Paffenbarger, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulo, A. Tzonou, A. Dabancen, L. Martinez, R. Molina, O. Sala, M. T. Goodman, G. Lurie, M. E. Carney, L. R. Wilken, L. Hartman, J. Manjer, H. Olsson, J. A. Grisso, M. Morgan, J. E. Wheeler, C. H. Bunker, R. P. Edward, F. Modugno, P. H. M. Peeter, J. Casagrande, M. C. Pike, R. K. Ro, A. H. Wu, A. B. Miller, M. Kumle, I. T. Gram, E. Lund, L. Mcgowan, X. O. Shu, W. Zheng, T. M. M. Farley, S. Holck, O. Meirik, H. A. Risch, Epidemiologie, RS: CAPHRI School for Public Health and Primary Care, and RS: GROW - School for Oncology and Reproduction

Subjects
hormonal factor, Oncology, body-mass index, Comorbidity, anthropometric measurement, Body Mass Index, 0302 clinical medicine, Epidemiology, Cancer Type - Ovarian Cancer, 030212 general & internal medicine, epithelial ovarian, Prospective cohort study, oral contraceptives, Ovarian Neoplasms, Incidence (epidemiology), Incidence, Smoking, Articles, Middle Aged, Adenocarcinoma, Mucinous, 3. Good health, Causality, Europe, risk-factor, Serous fluid, 030220 oncology & carcinogenesis, Meta-analysis, Adenocarcinoma, Female, Risk, Adult, medicine.medical_specialty, prospective cohort, Etiology - Exogenous Factors in the Origin and Cause of Cancer, Risk Assessment, methods, 03 medical and health sciences, Internal medicine, oral-contraceptive use, medicine, cancer, Humans, Women, tobacco smoking, therapy, cigarette-smoking, VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762, business.industry, Research, medicine.disease, VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762, Relative risk, North America, Other, United-State, business, Ovarian cancer, Meta-Analysis
Abstract

BACKGROUND: Smoking has been linked to mucinous ovarian cancer, but its effects on other ovarian cancer subtypes and on overall ovarian cancer risk are unclear, and the findings from most studies with relevant data are unpublished. To assess these associations, we review the published and unpublished evidence. METHODS: Eligible epidemiological studies were identified by electronic searches, review articles, and discussions with colleagues. Individual participant data for 28,114 women with and 94,942 without ovarian cancer from 51 epidemiological studies were analysed centrally, yielding adjusted relative risks (RRs) of ovarian cancer in smokers compared with never smokers. FINDINGS: After exclusion of studies with hospital controls, in which smoking could have affected recruitment, overall ovarian cancer incidence was only slightly increased in current smokers compared with women who had never smoked (RR 1·06, 95% CI 1·01-1·11, p=0·01). Of 17,641 epithelial cancers with specified histology, 2314 (13%) were mucinous, 2360 (13%) endometrioid, 969 (5%) clear-cell, and 9086 (52%) serous. Smoking-related risks varied substantially across these subtypes (p(heterogeneity)

Published
2016

30. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies - International collaboration of epidemiological studies of cervical cancer

Author

Rajkumar, T, Appleby, P, Beral, V, Berrington, D, Bull, D, Crossley, B, Green, J, Reeves, G, Sweetland, S, Kjaer, S, Peto, J, Painter, R, Vessey, M, Daling, J, Madeleine, M, Ray, R, Thomas, D, Hutchinson, F, Hererro, R, Ylitalo, N, Bosch, F, Castellsague, X, Hammouda, D, and Negri, E

Published
2016

32. SUPPLEMENT: Proceedings of the Seventeenth Biennial Council of Pi Lambda Theta Cornell University

Author

Bartelme, Jean, Pearsun, Helen, Fahy, Anne, Pease, Katharine, Crossley, B. Alice, Chisholm, Thelma, Smith, Margaret Ruth, Tatum, Beulah Benton, Wooden, Ethel, Veon, Dorothy H., Cabell, Maud, Fratcher, Florene B., Fugate, Josephine, Lidolph, Dorothy E., Kuhlmann, Martha J., Murphy, Nell A., Warren, Elizabeth S., Trefz, Lettie, Brockman, Martha, Clapp, Helen W., Coppola, Theresa, Harris, Ruth, Ohlheiser, Frances, Walker, Helen, Sullivan, Helen Blair, Biggy, M. Virginia, Clarson, Gertrude, Hall, Marguerite F., Wells, Florence H., Wilson, Elizabeth K., Steele, Eileen French, Dungan, Eleanor T., Hartley, Helene, McCabe, Marie, Steinmetz, Kathryn, Bergen, Mary, Holzboog, Kathy, Kudzia, Wilma, Loane, Helen, Platt, Grace, Strickland, Ruth, Boynton, Ruth, Campbell, Joan, Huggard, Betty, Dixon, Louise Markhus, Tomer, Martha, Truscott, Natalie, Shine, Roberta, La Caff, Maurine, Seagoe, May, Swensen, Betty Spornitz, Dickman, Martha, Junker, Gladys M. Willcutt, Reinking, Esther A., Schaller, Martha K., Stanton, Jeannette, Coe, Ellen, Nittler, Marilyn, Christensen, Dorothy J., Barnes, Thelma, and Partridge, Deborah C.

Published
1951

34. SUPPLEMENT: Proceedings of the Nineteenth Biennial Council of Pi Lambda Theta University of Michigan Ann Arbor, Michigan August 23-26 1955

Author

Tatum, Beulah Benton, Baxter, Bernice, Biggy, M. Virginia, Dakin, Dorothy, Sornson, Helen H., Wiles, Marion E., Wilson, Grace, Pearson, Helen R., Beardsley, Katharine Pease, Coryell, Gladys A., Johnson, Carmen, Gowan, May Seagoe, Hamilton, Frances, Wulfekammer, Verna, Cazel, Fern, Harris, Ruth, Tuthill, Charlotte, Worley, Vivienne, Winson, Grace, Crosley, Marilyn Williams, Davidson, Ethelyn, DeNevers, Margaret, Herold, Talitha, Jones, Alma Ward, Mauney, Connie Freeman, Neill, Mary, Roberts, Ruth, Walters, Maxine Oyler, Warner, Welcome, Williams, D. Joan, Wolfe, Ethel, Sanderson, Marjorie, Cotton, Ruth, Lyda, Frieda A., Pickard, Dorothy E., Williams, Merea, Wooden, Ethel, Anderson, Ruth, Arends, Muriel, Baker, Mabel Love, Canary, Nancy, Clark, Nancy Jane, Delaney, Agnes, Hall, Edythe, Nickerson, Marion Stenton, Pellett, Elizabeth, Scott, Esther, Shannon, Marguerite, Walvoord, Margaret, Aandahl, Marilyn, Asai, Mitzi, Crane, Nancy, Davidson, Edith, Downs, Marie, Duncan, Doris Anne Proctor, Johnson, Hazel, Richardson, Adeline Claff, Sheets, Margaret, Tinker, Marie, Tripp, Maxine, Veon, Dorothy H., Weisman, Frances, Crossley, B. Alice, Curtis, Patsy, Fallon, Mary, Green, Mildred, Hawkins, Katharine, Joyce, Virginia C., Keily, Helen J., Lewis, Ruth Krandis, Loesche, Marion S., Moore, Marie, Noble, Jeanne, Oliverio, Mary Ellen, Owen, Kathleen, Harris, Eva, Kaar, Galeta, Ling, Shata, McFarland, Mildred, Meador, Bettye, Mickelson, Esther, Owen, Louise, Sowinski, Victoria Lang, Thornton, Sally, Shine, Roberta, Martinson, Ruth, Spaney, Emma, Swineford, Frances, Tyler, Leona, Adams, Georgia Sachs, Barnes, Thelma, Cummings, Virginia, Dillon, Helen, Galvin, Corinne, Schweppe, Erna, Morris, Terry Hastings, Chisholm, Thelma, Colton, Carolyn Carson, Fox, Alice, Handy, Martha Pauline, Hughes, Mildred, Smith, Margaret Ruth, Smith, Mary Jane, Solomon, Ruth, Strunk, Marie, Siebert, Edna M., Doolittle, Nettie-Alice, Fratcher, Florene, Haynes, Nola Lee, Steele, Eileen French, Batie, Harriett, Clauve, Lena, Hajek, Norma, Mitchell, Caroline, Mitchell, Caroline G., Wilkins, Winnie, Hooper, Laura, Lybeck, Caroline G., Terry, Miriam, Thompson, Helen M., Samuelson, Agnes, Cook, Sarah Louise, McHugh, Olive, Van Wagenen, Beulah C., Ault, Ruth M., Cuskaden, Clarice, Sundermann, Betty L., Beatty, Angela Mensing, Call, Marilyn, Lemke, Anna K., Luthy, Annette, Mouradian, Esther, and Beltramo, Louise

Published
1955

35. Proceedings of the Eighteenth Biennial Council of Pi Lambda Theta University of New Mexico Albuquerque, New Mexico August 18-21 1953

Author

Tatum, Beulah Benton, Crossley, B. Alice, Baxter, Bernice, Harris, Ruth M., Smith, Margaret Ruth, Dakin, Dorothy, Wilson, Grace, Veon, Dorothy H., Pearson, Helen R., Mugford, Ruth Marshall, Coryell, Gladys A., Lang, Mary Jane, Pearson, Helen, Strunk, Marie, Trefz, Lettie, Harris, Ruth, Campbell, Joan, Dunphy, Gladys, Edwards, Marcia, Hamrin, Hazel, Hollenbeck, Edna, Huggard, Betty, Tinker, Marie, Chisholm, Thelma, Benjamin, Georgia K., Cotton, Ruth, Olson, M. Adeline, Lyda, Frieda A. Renfro, Williams, Merea, Wooden, Ethel, Allen, Margaret, Borg, Ida, Chatterley, Lois, Cowell, Jane, Cruikshank, Annabelle, Helmreich, Marilyn Nittler, Hartley, Helene, Kemp, Alice, McFall, Katharine, Martinson, Ruth, Merrill, Anne, Reese, Mary Jane, Arends, Muriel, Bishop, Matilda, Coombs, Winnifred, Doty, Dorothy, Hooper, Laura, Kuhlmann, Martha, Seidel, Yvonne Whitehurst, Smith, Johnnie Rutland, Stark, Mabel Claire, Bible, Margaret K., Biggy, M. Virginia, de Coligny, Marion, Drummond, Laura W., Jones, Anna M., Lohr, Helen, Loy, Helen, McCabe, Marie E., Niland, Adella, Ackermann, Mary Ann, Barnes, Thelma, Bergen, Mary A., Burns, Mary Aikin, Geweke, Lenore, Harpster, Dorothy, Johnston, Vera, Kitson, Mary, Pipkin, Glenda, Reese, Doris, Rupel, Maud, Ruslander, Zella, Wilkins, Winnie, Kaar, Galeta, Davis, Sarita, Edman, Marion, Hess, Dorothy, Kiefer, Emma E., Shine, Roberta, Dowell, Anita S., Hale, Helen E., McMahon, Clara P., Delaney, Agnes, Hartje, Elizabeth, Loane, Helen J., Seagoe, May V., Freeman, Connie Pat, Lowe, Alberta, Caporale, Josephine, Christensen, Dorothy, Dungan, Eleanor, Fratcher, Florene, Esteros, Gertrude, de Cologny, Marion, Vopni, Sylvia, Samuelson, Agnes, Van Wagenen, Beulah, Doolittle, Nettie-Alice, Haynes, Nola Lee, Steele, Eileen French, Damon, Patricia A., Jordan, Myrtle K., Herbst, Frieda, Stelzriede, Helen M., Dunfee, Maxine, Varias, Josie R., Loesche, Marion S., Webster, Harriet, Terry, Miriam, and Mugford, Ruth M.

Published
1953

38. Menopausal hormone use and ovarian cancer risk : Individual participant meta-analysis of 52 epidemiological studies

Author

Gapstur, S. M., Patel, A. V., Banks, E., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Beral, V., Bull, D., Cairns, B., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Hermon, C., Key, T., Moser, K., Reeves, G., Sitas, F., Collins, R., Peto, R., Gonzalez, C. A., Lee, N., Marchbanks, P., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Goodman, M. T., Lidegaard, O., Kjaer, S. K., Morch, L. S., Tjonneland, A., Byers, T., Rohan, T., Mosgaard, B., Vessey, M., Yeates, D., Freudenheim, J. L., Titus, L. J., Chang-Claude, J., Kaaks, R., Anderson, K. E., Lazovich, D., Robien, K., Hampton, J., Newcomb, P. A., Rossing, M. A., Thomas, D. B., Weiss, N. S., Lokkegaard, E., Riboli, E., Clavel-Chapelon, F., Cramer, D., Hankinson, S. E., Tamimi, R. M., Tworoger, S. S., Franceschi, S., La Vecchia, C., Negri, E., Adami, H. O., Magnusson, C., Riman, T., Weiderpass, E., Wolk, A., Schouten, L. J., van den Brandt, P. A., Chantarakul, N., Koetsawang, S., Rachawat, D., Palli, D., Black, A., Brinton, L. A., Freedman, D. M., Hartge, P., Hsing, A. W., Jnr, J. V. Lacey, Lissowska, J., Hoover, R. N., Schairer, C., Babb, C., Urban, M., Graff-Iversen, S., Selmer, R., Bain, C. J., Green, A. C., Purdie, D. M., Siskind, V., Webb, P. M., Moysich, K., McCann, S. E., Hannaford, P., Kay, C., Binns, C. W., Lee, A. H., Zhang, M., Ness, R. B., Nasca, P., Coogan, P. F., Palmer, J. R., Rosenberg, L., Whittemore, A., Katsouyanni, K., Trichopoulou, A., Trichopoulos, D., Tzonou, A., Dabancens, A., Martinez, L., Molina, R., Salas, O., Lurie, G., Carney, M. E., Wilkens, L. R., Werner Hartman, Linda, Manjer, Jonas, Olsson, Håkan, Kumle, M., Grisso, J. A., Morgan, M., Wheeler, J. E., Edwards, R. P., Kelley, J. L., Modugno, F., Onland-Moret, N. C., Peeters, P. H. M., Casagrande, J., Pike, M. C., Wu, A. H., Canfell, K., Miller, A. B., Gram, I. T., Lund, E., McGowan, L., Shu, X. O., Zheng, W., Farley, T. M. M., Holck, S., Meirik, O., Risch, H. A., S. M. Gapstur, A. V. Patel, E. Bank, L. Dal Maso, R. Talamini, A. Chetrit, G. Hirsh Yechezkel, F. Lubin, S. Sadetzki, V. Beral, D. Bull, B. Cairn, B. Crossley, K. Gaitskell, A. Goodill, J. Green, C. Hermon, T. Key, K. Moser, G. Reeve, F. Sita, R. Collin, R. Peto, C. A. Gonzalez, N. Lee, P. Marchbank, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, M. T. Goodman, O. Lidegaard, S. K. Kjaer, L. S. Morch, A. Tjonneland, T. Byer, T. Rohan, B. Mosgaard, M. Vessey, D. Yeate, J. L. Freudenheim, L. J. Titu, J. Chang Claude, R. Kaak, K. E. Anderson, D. Lazovich, K. Robien, J. Hampton, P. A. Newcomb, M. A. Rossing, D. B. Thoma, N. S. Wei, E. Lokkegaard, E. Riboli, F. Clavel Chapelon, D. Cramer, S. E. Hankinson, R. M. Tamimi, S. S. Tworoger, S. Franceschi, C. La Vecchia, E. Negri, H. O. Adami, C. Magnusson, T. Riman, E. Weiderpa, A. Wolk, L. J. Schouten, P. A. van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, D. Palli, A. Black, L. A. Brinton, D. M. Freedman, P. Hartge, A. W. Hsing, J. V. L. Jnr, J. Lissowska, R. N. Hoover, C. Schairer, C. Babb, M. Urban, S. Graff Iversen, R. Selmer, C. J. Bain, A. C. Green, D. M. Purdie, V. Siskind, P. M. Webb, K. Moysich, S. E. McCann, P. Hannaford, C. Kay, C. W. Binn, A. H. Lee, M. Zhang, R. B. Ne, P. Nasca, P. F. Coogan, J. R. Palmer, L. Rosenberg, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulo, A. Tzonou, A. Dabancen, L. Martinez, R. Molina, O. Sala, G. Lurie, M. E. Carney, L. R. Wilken, L. Hartman, J. Manjer, H. Olsson, M. Kumle, J. A. Grisso, M. Morgan, J. E. Wheeler, R. P. Edward, J. L. Kelley, F. Modugno, N. C. Onland Moret, P. H. M. Peeter, J. Casagrande, M. C. Pike, A. H. Wu, K. Canfell, A. B. Miller, I. T. Gram, E. Lund, L. McGowan, X. O. Shu, W. Zheng, T. M. M. Farley, S. Holck, O. Meirik, H. A. Risch, Epidemiologie, RS: CAPHRI School for Public Health and Primary Care, RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, RS: CAPHRI - R5 - Optimising Patient Care, RS: GROW - Oncology, and RS: GROW - R1 - Prevention

Subjects
medicine.medical_specialty, medicine.medical_treatment, Etiology - Endogenous Factors in the Origin and Cause of Cancer, ovarian neoplasm, THERAPY, Medicine, General & Internal, Internal medicine, General & Internal Medicine, Epidemiology, middle aged, medicine, Cancer Type - Ovarian Cancer, estrogen replacement therapy, human, Prospective cohort study, medicine (all), Gynecology, Science & Technology, business.industry, drug administration schedule, WOMEN, risk assessment, Retrospective cohort study, General Medicine, 11 Medical And Health Sciences, medicine.disease, postmenopause, female, Meta-analysis, Relative risk, Cancer and Oncology, incidence, Hormone therapy, HEALTH, Risk assessment, Ovarian cancer, business, Life Sciences & Biomedicine
Abstract

SummaryBackgroundHalf the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk.MethodsIndividual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use.FindingsDuring prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with

Published
2015

39. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

Author

Gapstur, S. M. Patel, A. V. Banks, E. Dal Maso, L. and Talamini, R. Chetrit, A. Hirsh-Yechezkel, G. Lubin, F. and Sadetzki, S. Beral, V. Bull, D. Cairns, B. Crossley, B. and Gaitskell, K. Goodill, A. Green, J. Hermon, C. Key, T. Moser, K. Reeves, G. Sitas, F. Collins, R. Peto, R. Gonzalez, C. A. Lee, N. Marchbanks, P. Ory, H. W. and Peterson, H. B. Wingo, P. A. Martin, N. Silpisornkosol, S. and Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. and Virutamasen, P. Wongsrichanalai, C. Goodman, M. T. and Lidegaard, O. Kjaer, S. K. Morch, L. S. Tjonneland, A. and Byers, T. Rohan, T. Mosgaard, B. Vessey, M. Yeates, D. and Freudenheim, J. L. Titus, L. J. Chang-Claude, J. Kaaks, R. Anderson, K. E. Lazovich, D. Robien, K. Hampton, J. and Newcomb, P. A. Rossing, M. A. Thomas, D. B. Weiss, N. S. and Lokkegaard, E. Riboli, E. Clavel-Chapelon, F. Cramer, D. and Hankinson, S. E. Tamimi, R. M. Tworoger, S. S. and Franceschi, S. La Vecchia, C. Negri, E. Adami, H. O. and Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. and Schouten, L. J. van den Brandt, P. A. Chantarakul, N. and Koetsawang, S. Rachawat, D. Palli, D. Black, A. Brinton, L. A. Freedman, D. M. Hartge, P. Hsing, A. W. Jnr, J. V. Lacey Lissowska, J. Hoover, R. N. Schairer, C. Babb, C. and Urban, M. Graff-Iversen, S. Selmer, R. Bain, C. J. and Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. and Moysich, K. McCann, S. E. Hannaford, P. Kay, C. Binns, C. W. Lee, A. H. Zhang, M. Ness, R. B. Nasca, P. and Coogan, P. F. Palmer, J. R. Rosenberg, L. Whittemore, A. and Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. Tzonou, A. and Dabancens, A. Martinez, L. Molina, R. Salas, O. and Lurie, G. Carney, M. E. Wilkens, L. R. Hartman, L. and Manjer, J. Olsson, H. Kumle, M. Grisso, J. A. Morgan, M. and Wheeler, J. E. Edwards, R. P. Kelley, J. L. Modugno, F. and Onland-Moret, N. C. Peeters, P. H. M. Casagrande, J. and Pike, M. C. Wu, A. H. Canfell, K. Miller, A. B. Gram, I. T. Lund, E. McGowan, L. Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. Risch, H. A. Collaborative Grp Epidemiological

Abstract

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with

Published
2015

40. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies - International collaboration of epidemiological studies of cervical cancer

Author

Rajkumar, T., Appleby, P., Beral, V., Berrington, Da, Bull, D., Crossley, B., Green, J., Reeves, G., Sweetland, S., Kjaer, S., Peto, J., Painter, R., Vessey, M., Daling, J., Madeleine, M., Ray, R., Thomas, D., Hutchinson, F., Hererro, R., Ylitalo, N., Bosch, Fx, Castellsague, X., Hammouda, D., Eva Negri, Santos, C., Colin, D., Franceschi, S., Munoz, N., Plummer, M., Dillner, J., Bayo, S., Chaouki, N., Rolon, P., Brinton, L., Hildesheim, A., Lacey, J., Schiffman, M., Stein, L., Hannaford, P., Chichareon, S., Sitas, F., Eluf-Neto, J., La Vecchia, C., Skegg, D., Pike, M., Ursin, G., Ngelangel, C., Farley, T., Meirik, O., Rajkumar T, Appleby P, Beral V, Berrington DA, Bull D, Crossley B, Green J, Reeves G, Sweetland S, Kjaer S, Peto J, Painter R, Vessey M, Daling J, Madeleine M, Ray R, Thomas D, Hutchinson F, Hererro R, Ylitalo N, Bosch FX, Castellsague X, Hammouda D, Negri E, Santos C, Colin D, Franceschi S, Munoz N, Plummer M, Dillner J, Bayo S, Chaouki N, Rolon P, Brinton L, Hildesheim A, Lacey J, Schiffman M, Stein L, Hannaford P, Chichareon S, Sitas F, Eluf-Neto J, La Vecchia C, Skegg D, Pike M, Ursin G, Ngelangel C, Farley T, and Meirik O

Abstract

Tobacco smoking has been classified as a cause of cervical cancer, but the effect of different patterns of smoking on risk is unclear. The International Collaboration of Epidemiological Studies of Cervical Cancer has brought together and combined individual data on 13,541 women with and 23,017 women without cervical carcinoma, from 23 epidemiological studies. Relative risks (RRs) and 95% confidence intervals (CIs) of carcinoma of the cervix in relation to tobacco smoking were calculated with stratification by study, age, sexual partners, age at first intercourse, oral contraceptive use and parity. Current smokers had a significantly increased risk of squamous cell carcinoma of the cervix compared to never smokers (RR = 1.60 (95% CI: 1.48-1.73), p < 0.001). There was increased risk for past smokers also, though to a lesser extent (RR = 1.12 (1.01-1.25)), and there was no clear trend with time since stopping smoking (p-trend = 0.6). There was no association between smoking and adenocarcinoma of the cervix (RR = 0.89 (0.74-1.06) and 0.89 (0.72-1.10) for current and past smokers respectively), and the differences between the RRs for smoking and squamous cell and adenocarcinoma were statistically significant (current smoking p < 0.001 and past smoking p = 0.01). In current smokers, the RR of squamous cell carcinoma increased with increasing number of cigarettes smoked per day and also with younger age at starting smoking (p < 0.001 for each trend), but not with duration of smoking (p-trend = 0.3). Eight of the studies had tested women for cervical HPV-DNA, and in analyses restricted to women who tested positive, there was a significantly increased risk in current compared to never smokers for squamous cell carcinoma (RR = 1.95 (1.43-2.65)), but not for adenocarcinoma (RR = 1.06 (0.14-7.96)). In summary, smokers are at an increased risk of squamous cell but not of adenocarcinoma of the cervix. The risk of squamous cell carcinoma increases in current smokers with the number of cigarettes smoked per day and with younger age at starting smoking. (c) 2005 Wile-y-Liss. Inc. RI Eluf-Neto, Jose/B-2522-2009

Published
2006

41. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

Author

Epi Kanker Team 1, JC onderzoeksprogramma Kanker, Cancer, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Gapstur, S. M., Patel, A. V., Banks, E., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Beral, V., Bull, D., Cairns, B., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Hermon, C., Key, T., Moser, K., Reeves, G., Sitas, F., Collins, R., Peto, R., Gonzalez, C. A., Lee, N., Marchbanks, P., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Goodman, M. T., Lidegaard, O., Kjaer, S. K., Morch, L. S., Tjonneland, A., Byers, T., Rohan, T., Mosgaard, B., Vessey, M., Yeates, D., Onland-Moret, N. C., Peeters, P. H. M., Collaborative Grp Epidemiological, Epi Kanker Team 1, JC onderzoeksprogramma Kanker, Cancer, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Gapstur, S. M., Patel, A. V., Banks, E., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Beral, V., Bull, D., Cairns, B., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Hermon, C., Key, T., Moser, K., Reeves, G., Sitas, F., Collins, R., Peto, R., Gonzalez, C. A., Lee, N., Marchbanks, P., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Goodman, M. T., Lidegaard, O., Kjaer, S. K., Morch, L. S., Tjonneland, A., Byers, T., Rohan, T., Mosgaard, B., Vessey, M., Yeates, D., Onland-Moret, N. C., Peeters, P. H. M., and Collaborative Grp Epidemiological

Published
2015

42. Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease

Author

Peterson, B., Ontiveros, P., Yu, M. C., Heath, C. W., Bergkvist, L., Baines, C. J., Malone, K., Magnusson, C., Lubin, F., Kungu, A., Kay, C., Pike, M., Siskind, V., Virutamasen, P., Hermon, C., Brêmond, A., Lacaya, L. B., Bain, C., Calle, E. E., Aristizabal, N., Gatei, D., Ngelangel, C. A., Bull, D., Fentiman, I. S., Leske, M. C., Hannaford, P., Pike, M. C., Viladiu, P., Wang, D. Y., Peto, J., White, E., Weinstein, A. L., Theetranont, C., Fraser, G., La Vecchia, C., Martinez, L., Evstifeeva, T., Holck, S., Jin, F., Shearman, R., Nasca, P. C., Wang, Q. S., Stanford, J. L., Chilvers, C. E.D., Tulinius, H., Bishop, T., Coldman, A. J., Salazar, S. B., Gallagher, R. P., Peto, R., Reeves, G., Hiatt, R. A., Kunde, D., Boyle, P., Kenya, P., Molina, R., Salas, O., Negri, E., Liff, J. M., Primic-Zakelj, M., Lee, N., Doll, R., Anderson, K., Schairer, C., Band, P., Goodill, A., Goldbohm, R. A., Katsouyanni, K., Hu, J., Mao, Y., Noonan, E. A., Hislop, T. G., Meirik, O., Cuadros, A., Clavel, F., Ursin, G., Boosiri, B., Lansac, J., Schofield, F., Renaud, R., Kosmelj, K., Kolonel, L. M., Hulka, B., Berry, G., Daling, J. R., Jones, L., Mati, J. G., Hulka, B. S., McCredie, M., Spears, G. F.S., Trichopoulou, A., Schuman, L., Farley, T. M.M., Ravnihar, B., Wei, H. Y., Key, T., Skegg, D. C.G., Lewis, C., Bernstein, L., Miller, A. B., Hanson, R. L., Ross, R. K., Martin, N., Rohan, T., Collins, R., Yuan, J. M., Colditz, G., Gao, Y. T., MacLennan, R., Segala, C., Weiss, N. S., Cooper Booth, J., Andrieu, N., Banks, E., Richardson, S., van Leeuwen, F. E., Newcomb, P., Gammon, M. D., Wongsrichanalai, C., Friedman, G. D., Szklo, M., Baens, J., van den Brandt, P. A., Alexander, F. E., Wilson, H. G., Spirtas, R., Tajima, K., Gerber, M., Franceschi, S., Stare, J., Ron, E., Jelihovsky, T., Mabuchi, K., Piana, L., Wall, C., Schoenberg, J. A., Koetsawang, S., Apelo, R. A., Marchbanks, P., Stewart, W., Van Leeuven, M., Jimakorn, P., Beeson, W. L., Pardthaisong, T., Tryggvadottir, L., Zheng, W., Adami, H. O., Coates, R. J., Palet, A., Wingo, P. A., Thomas, D. B., Thomas, D., Enger, S., Trichopoulos, D., Chutivongse, S., Bulbrook, R. D., Rosero-Bixby, L., Gajalakshmi, V., de la Cruz, J. R., Hopper, J. L., Muller, A., Zhiheng, C., Beral, V., Hamajima, N., Ewertz, M., Varma, A. O., Nomura, A. M.Y., Rookus, M. A., Lee, H. P., Ebeling, K., Cuzick, J., Yang, P., Cuevas, H. R., Peterson, H. B., Izquierdo, A., Brinton, L. A., Nishan, P., Clarke, E. A., Hayward, J. L., Crossley, B., Yun, T., Kalache, A., Moller, T. R., Hutchinson, W. B., Green, J., Marubini, E., Hoover, R., Wax, Y., Modan, B., Ory, H. W., Duffy, S. W., Ranstam, J., Olsson, H., Lund, E., Gairard, B., Ferraroni, M., Paganini-Hill, A., Appleby, P., Shu, X. O., Vessey, M., Haile, R. W., Dabancens, A., Folsom, A. R., Langston, N., Talamini, R., Skegg, D., Neil, A., Chang-Claude, J., Bachelot, A., McMichael, A. J., Javier, B., Persson, I., Paul, C., Mahoney, M. C., Hirose, K., Rachawat, D., De Sanjosé, S., Longnecker, M. P., Johnson, K. C., Morabia, A., Preston, D., Levi, F., Silpisornkosol, S., Stalsberg, H., McPherson, K., Yeates, D., Lê, M. G., Chantarakul, N., Clavel-Chapelon, F., Secretariat, Cancer Research UK Epidemiology Unit, Beral V, Hamajima N, Hirose K, Rohan T, Calle EE, Heath CW, Coates RJ, Liff JM, Talamini R, Chantarakul N, Koetsawang S, Rachawat D, Morabia A, Schuman L, Stewart W, Szklo M, Bain C, Schofield F, Siskind V, Band P, Coldman AJ, Gallagher RP, Hislop TG, Yang P, Kolonel LM, Nomura AMY, Hu J, Johnson KC, Mao Y, De Sanjose S, Lee N, Marchbanks P, Ory HW, Peterson HB, Wilson HG, Wingo PA, Ebeling K, Kunde D, Nishan P, Hopper JL, Colditz G, Gajalakshmi V, Martin N, Pardthaisong T, Solpisornkosol S, Theetranont C, Boosiri B, Chutivongse S, Jimakorn P, Virutamasen P, Wongsrichanalai C, Ewertz M, Adami HO, Bergkvist L, Magnusson C, Persson I, Chang-Claude J, Paul C, Skegg DCG, Spears GFS, Boyle P, Evstifeeva T, Daling JR, Hutchinson WB, Malone K, Noonan EA, Stanford JL, Thomas DB, Weiss NS, White E, Andrieu N, Bremond A, Clavel F, Gairard B, Lansac J, Piana L, Renaud R, Izquierdo A, Viladiu P, Cuevas HR, Ontiveros P, Palet A, Salazar SB, Arsitizabal N, Cuadros A, Tryggvadottir L, Tulinius H, Bachelot A, Le MG, Peto J, Franceschi S, Lubin F, Modan B, Ron E, Wax Y, Friedman GD, Hiatt RA, Levi F, Bishop T, Kosmelj K, Primic-Zakelj M, Ravnihar B, Stare J, Beeson WL, Fraser G, Bulbrook RD, Cuzick J, Duffy SW, Fentiman IS, Hayward JL, Wang DY, McMichael AJ, McPherson K, Hanson RL, Leske MC, Mahoney MC, Nasca PC, Varma AO, Weinstein AL, Moller TR, Olsson H, Ranstam J, Goldbohm RA, van den Brandt PA, Apelo RA, Baens J, de la Cruz JR, Javier B, Lacaya LB, Ngelangel CA, La Vecchia C, Negri E, Marubini E, Ferraroni M, Gerber M, Richardson S, Segala C, Gatei D, Kenya P, Kungu A, Mati JG, Brinton LA, Hoover R, Schairer C, Spirtas R, Lee HP, Rookus MA, van Leeuwen FE, Schoenberg JA, McCredie M, Gammon MD, Clarke EA, Jones L, Neil A, Vessey M, Yeates D, Appleby P, Banks E, Bull D, Crossley B, Goodill A, Green J, Hermon C, Key T, Langston N, Lewis C, Reeves G, Collins R, Doll R, Peto R, Mabuchi K, Preston D, Hannaford P, Kay C, Rosero-Bixby L, Gao YT, Jin F, Yuan JM, Wei HY, Yun T, Zhiheng C, Berry G, Cooper Booth J, Jelihovsky T, MacLennan R, Shearman R, Wang QS, Baines CJ, Miller AB, Wall C, Lund E, Stalsberg H, Shu XO, Zheng W, Katsouyanni K, Trichopoulou A, Trichopoulos D, Dabancens A, Martinez L, Molina R, Salas O, Alexander XE, Anderson K, Folsom AR, Hulka BS, Bernstein L, Enger S, Haile RW, Paganini-Hill A, Pike MC, Ross RK, Ursin G, Yu MC, Longnecker MP, Newcomb P, Kalache A, Farley TMM, Holck S, Meirik O, and Universitat de Barcelona

Subjects
Cancer Research, medicine.medical_specialty, Epidemiology, Dones, Alcohol, tobacco, smoking, Càncer de mama, chemistry.chemical_compound, Breast cancer, Hàbit de fumar, breast cancer, Tabac, Tobacco, [SDV.SPEE] Life Sciences [q-bio]/Public Health and Epidemiology, medicine, Women, Gynecology, collaborative reanalysis, Obstetrics, business.industry, alcohol, Confounding, Smoking, medicine.disease, Tobbacco habit, Oncology, chemistry, Drinking of alcoholic beverages, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Meta-analysis, Relative risk, Consum d'alcohol, Risk assessment, business, Developed country
Abstract

COLLABORATORS (in alphabetical order of institution, study name, or location) Aichi Cancer Research Institute, Nagoya, Japan: N Hamajima, K Hirose, K Tajima; Albert Einstein College of Medicine, NY, USA: T Rohan; American Cancer Society, GA, USA: EE Calle, CW Jr Heath; Atlanta, Emory University, GA, USA: RJ Coates, JM Liff; Aviano Cancer Center, Pordenone, Italy: R Talamini; Mahidol University, Bangkok, Thailand: N Chantarakul, S Koetsawang, D Rachawat; Breast Tumor Collaborative Study, Johns Hopkins University, MD, USA: A Morabia, L Schuman, W Stewart, M Szklo; University of Queensland, Brisbane, Australia: C Bain, F Schofield, V Siskind; British Columbia Cancer Agency, BC, Canada: P Band, AJ Coldman, RP Gallagher, TG Hislop, P Yang; Cancer Research Center, University of Hawaii, Hawaii, USA: LM Kolonel, AMY Nomura; Canadian Cancer Registries Epidemiology Research Group, Canada: J Hu, KC Johnson, Y Mao; Catalán Institut of Oncology, Barcelona, Spain: S De Sanjosé; Centers for Disease Control & Prevention, GA, USA: N Lee, P Marchbanks, HW Ory, HB Peterson, HG Wilson, PA Wingo; Central Institute of Cancer Research, Berlin, Germany: K Ebeling, D Kunde, P Nishan; Centre for Genetic Epidemiology, University of Melbourne, Melbourne, Australia: JL Hopper; Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, MA, USA: G Colditz for Nurses' Health Study Research Group; Chennai Cancer Institute, Madras, India: V Gajalakshmi; Chiang Mai University, Chiang Mai, Thailand: N Martin, T Pardthaisong, S Silpisornkosol, C Theetranont; Chulalongkorn University, Bangkok, Thailand: B Boosiri, S Chutivongse, P Jimakorn, P Virutamasen, C Wongsrichanalai; Danish Cancer Society, Aalborg, Denmark: M Ewertz; Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden: HO Adami, L Bergkvist, C Magnusson, I Persson; Deutsches Krebsforschungszentrum, Heidelberg, Germany: J Chang-Claude; University of Otago, Dunedin, New Zealand: C Paul, DCG Skegg, GFS Spears; European Institute of Oncology, Milan, Italy: P Boyle, T Evstifeeva; Fred Hutchinson Cancer Research Center, WA, USA: JR Daling, WB Hutchinson, K Malone, EA Noonan, JL Stanford, DB Thomas, NS Weiss, E White; French Multicentre Breast Study, INSERM, Villejuif, France: N Andrieu, A Brêmond, F Clavel, B Gairard, J Lansac, L Piana, R Renaud; Girona Cancer Registry, Girona, Spain: A Izquierdo, P Viladiu; Hospital General de Mexico, Mexico City, Mexico: HR Cuevas, P Ontiveros, A Palet, SB Salazar; Hospital Universitario, Cali, Colombia: N Aristizabal, A Cuadros; Icelandic Cancer Society, Reykjavik, Iceland: L Tryggvadottir, H Tulinius; INSERM, Institut Gustave-Roussey, Villejuif, France: A Bachelot, MG Lê; Institute of Cancer Research, Sutton and London School of Hygiene and Tropical Medicine, UK: J Peto; International Agency for Research in Cancer, Lyon, France: S Franceschi; Israel Chaim Sheba Medical Centre, Tel-Hashomer, Israel: F Lubin, B Modan, E Ron, Y Wax; Kaiser Permanente, CA, USA: GD Friedman, RA Hiatt; Institut universitaire de medecine sociale et preventive, Lausanne, Switzerland: F Levi; Cancer Research UK Genetic Epidemiology Laboratory, Leeds, UK: T Bishop; Institute of Oncology, Ljubljana, Slovenia: K Kosmelj, M Primic-Zakelj, B Ravnihar, J Stare; Loma Linda University, CA, USA: WL Beeson, G Fraser; Cancer Research UK Department of Mathematics, Statistics & Epidemiology, London: RD Bulbrook, J Cuzick, SW Duffy, IS Fentiman, JL Hayward, DY Wang; London School of Hygiene & Tropical Medicine, London, UK: AJ McMichael, K McPherson; Long Island Breast Cancer Study, NY, USA: RL Hanson, MC Leske, MC Mahoney, PC Nasca, AO Varma, AL Weinstein; University Hospital, Lund, Sweden: TR Moller, H Olsson, J Ranstam; Maastricht University, Maastricht, The Netherlands: RA Goldbohm, PA van den Brandt; University of Philippines, Manila, Philippines: RA Apelo, J Baens, JR de la Cruz, B Javier, LB Lacaya, CA Ngelangel; Istituto ‘Mario Negri', Milan, Italy: C La Vecchia, E Negri; Istituto Nazionale Tumori, Divisione di Statistica Medica e Biometria, Milan, Italy: E Marubini; Istituto di Statistica Medica e Biometria, Milan, Italy: M Ferraroni; Montpellier Cancer Centre & INSERM, Montpellier, France: M Gerber, S Richardson, C Segala; Nairobi Centre for Research in Reproduction, Nairobi, Kenya: D Gatei, P Kenya, A Kungu, JG Mati; National Cancer Institute, MD, USA: LA Brinton, R Hoover, C Schairer; National Institute of Child Health & Human Development, MD, USA: R Spirtas; National University of Singapore, Singapore: HP Lee; The Netherlands Cancer Institute, Amsterdam, The Netherlands: MA Rookus, FE van Leeuwen for the Netherlands Oral Contraceptives and Breast Cancer Study Group; New Jersey State Department of Health, NJ, USA: JA Schoenberg; New South Wales Cancer Council, Sydney, Australia: M McCredie; Columbia University School of Public Health, NY, USA: MD Gammon; Ontario Cancer Treatment & Research Foundation, Ontario, Canada: EA Clarke; Department of Public Health & Primary Care, Oxford, UK: L Jones, A Neil, M Vessey, D Yeates; Cancer Research UK Epidemiology Unit, Oxford, UK (Secretariat): P Appleby, E Banks, V Beral, D Bull, B Crossley, A Goodill, J Green, C Hermon, T Key, N Langston, C Lewis, G Reeves; Cancer Research UK/MRC/BHF Clinical Trial Service Unit & Epidemiological Studies Unit, Oxford, UK: R Collins, R Doll, R Peto; Radiation Effects Research Foundation, Hiroshima, Japan: K Mabuchi, D Preston; Royal College of General Practitioners Oral Contraception Study, London, UK: P Hannaford, C Kay; University of Costa Rica, San Jose, Costa Rica: L Rosero-Bixby; Shanghai Cancer Institute, Shanghai, China: YT Gao, F Jin, J-M Yuan; Shanghai Institute of Planned Parenthood Research, Shanghai, China: HY Wei, T Yun, C Zhiheng; Department of Public Health, Sydney, Australia: G Berry, J Cooper Booth, T Jelihovsky, R MacLennan, R Shearman; Tianjin Cancer Institute, Tianjin, China: Q-S Wang; Department of Public Health Sciences, Toronto, Canada: CJ Baines, AB Miller, C Wall; Tromso University, Tromso, Norway: E Lund, H Stalsberg; Vanderbilt University, TN, USA: XO Shu, W Zheng; University of Athens Medical School, Athens, Greece: K Katsouyanni, A Trichopoulou, D Trichopoulos; University of Chile, Santiago, Chile: A Dabancens, L Martinez, R Molina, O Salas; University of Edinburgh, Edinburgh, UK: FE Alexander; University of Minnesota School of Public Health, MN, USA: K Anderson, AR Folsom on behalf of the Iowa Women's Health Study; University of North Carolina at Chapel Hill, School of Public Health, NC, USA: BS Hulka; University of Nottingham, Nottingham, UK: CED Chilvers; University of Southern California, LA, USA: L Bernstein, S Enger, RW Haile, A Paganini-Hill, MC Pike, RK Ross, G Ursin, MC Yu; University of Wisconsin Comprehensive Cancer Center, WI, USA: MP Longnecker, P Newcomb for the 4 State Study; Vasteras, Sweden: L Bergkvist; World Health Organisation, Geneva, Switzerland: A Kalache; World Health Organisation, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland: TMM Farley, S Holck, O Meirik. Analysis and writing committee: Beral V, Bull D, Doll R, Peto R, Reeves G Steering committee: Skegg D (Chairman), Colditz G, Hulka B, La Vecchia C, Magnusson C, Muller A, Peterson B, Pike M, Thomas D, Van Leeuven M.; International audience; Alcohol and tobacco consumption are closely correlated and published results on their association with breast cancer have not always allowed adequately for confounding between these exposures. Over 80% of the relevant information worldwide on alcohol and tobacco consumption and breast cancer were collated, checked and analysed centrally. Analyses included 58,515 women with invasive breast cancer and 95,067 controls from 53 studies. Relative risks of breast cancer were estimated, after stratifying by study, age, parity and, where appropriate, women's age when their first child was born and consumption of alcohol and tobacco. The average consumption of alcohol reported by controls from developed countries was 6.0 g per day, i.e. about half a unit/drink of alcohol per day, and was greater in ever-smokers than never-smokers, (8.4 g per day and 5.0 g per day, respectively). Compared with women who reported drinking no alcohol, the relative risk of breast cancer was 1.32 (1.19-1.45, P/=45 g per day alcohol. The relative risk of breast cancer increased by 7.1% (95% CI 5.5-8.7%; P

Published
2002
Full Text
View/download PDF

43. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies

Author

Beral, V, Bull, D, Pirie, K, Reeves, G, Peto, R, Skegg, D, LaVecchia, C, Magnusson, C, Pike, MC, Thomas, D, Hamajima, N, Hirose, K, Tajima, K, Rohan, T, Friedenreich, CM, Calle, EE, Gapstur, SM, Patel, AV, Coates, RJ, Liff, JM, Talamini, R, Chantarakul, N, Koetsawang, S, Rachawat, D, Marcou, Y, Kakouri, E, Duffy, SW, Morabia, A, Schuman, L, Stewart, W, Szklo, M, Coogan, PF, Palmer, JR, Rosenberg, L, Band, P, Coldman, AJ, Gallagher, RP, Hislop, TG, Yang, P, Cummings, SR, Canfell, K, Sitas, F, Chao, P, Lissowska, J, Horn-Ross, PL, John, EM, Kolonel, LM, Nomura, AMY, Ghiasvand, R, Hu, J, Johnson, KC, Mao, Y, Callaghan, K, Crossley, B, Goodill, A, Green, J, Hermon, C, Key, T, Lindgard, I, Liu, B, Collins, R, Doll, R, Bishop, T, Fentiman, IS, De Sanjose, S, Gonzaler, CA, Lee, N, Marchbanks, P, Ory, HW, Peterson, HB, Wingo, P, Ebeling, K, Kunde, D, Nishan, P, Hopper, JL, Eliassen, H, Gajalakshmi, V, Martin, N, Pardthaisong, T, Silpisornkosol, S, Theetranont, C, Boosiri, B, Chutivongse, S, Jimakorn, P, Virutamasen, P, Wongsrichanalai, C, Neugut, A, Santella, R, Baines, CJ, Kreiger, N, Miller, AB, Wall, C, Tjonneland, A, Jorgensen, T, Stahlberg, C, Pedersen, AT, Flesch-Janys, D, Hakansson, N, Cauley, J, Heuch, I, Adami, HO, Persson, I, Weiderpass, E, Chang-Claude, J, Kaaks, R, McCredie, M, Paul, C, Skegg, DCG, Spears, GFS, Iwasaki, M, Tsugane, S, Anderson, G, Daling, JR, Hampton, J, Hutchinson, WB, Li, CI, Malone, K, Mandelson, M, Newcomb, P, Noonan, EA, Ray, RM, Stanford, JL, Tang, MTC, Thomas, DB, Weiss, NS, White, E, Izquierdo, A, Viladiu, P, Fourkala, EO, Jacobs, I, Menon, U, Ryan, A, Cuevas, HR, Ontiveros, P, Palet, A, Salazar, SB, Aristizabal, N, Cuadros, A, Tryggvadottir, L, Tulinius, H, Riboli, E, Andrieu, N, Bachelot, A, Le, MG, Bremond, A, Gairard, B, Lansac, J, Piana, L, Renaud, R, Clavel-Chapelon, F, Fournier, A, Touillaud, M, Mesrine, S, Chabbert-Buffet, N, Boutron-Ruault, MC, Wolk, A, Torres-Mejia, G, Franceschi, S, Romieu, I, Boyle, P, Lubin, F, Modan, B, Ron, E, Wax, Y, Friedman, GD, Hiatt, RA, Levi, F, Kosmelj, K, Primic-Zakelj, M, Ravnihar, B, Stare, J, Ekbom, A, Erlandsson, G, Beeson, WL, Fraser, G, Peto, J, Hanson, RL, Leske, MC, Mahoney, MC, Nasca, PC, Varma, AO, Weinstein, AL, Hartman, ML, Olsson, H, Goldbohm, RA, van den Brandt, PA, Palli, D, Teitelbaum, S, Apelo, RA, Baens, J, de la Cruz, JR, Javier, B, Lacaya, LB, Ngelangel, CA, La Vecchia, C, Negri, E, Marubini, E, Ferraroni, M, Gerber, M, Richardson, S, Segala, C, Gatei, D, Kenya, P, Kungu, A, Mati, JG, Brinton, LA, Freedman, M, Hoover, R, Schairer, C, Ziegler, R, Banks, E, Spirtas, R, Lee, HP, Rookus, MA, van Leeuwen, FE, Schoenberg, JA, Graff-Iversen, S, Selmer, R, Jones, L, McPherson, K, Neil, A, Vessey, M, Yeates, D, Mabuchi, K, Preston, D, Hannaford, P, Kay, C, McCann, SE, Rosero-Bixby, L, Gao, YT, Jin, F, Yuan, J-M, Wei, HY, Yun, T, Zhiheng, C, Berry, G, Booth, JC, Jelihovsky, T, MacLennan, R, Shearman, R, Hadjisavvas, A, Kyriacou, K, Loisidou, M, Zhou, X, Wang, Q-S, Kawai, M, Minami, Y, Tsuji, I, Lund, E, Kumle, M, Stalsberg, H, Shu, XO, Zheng, W, Monninkhof, EM, Onland-Moret, NC, Peeters, PHM, Katsouyanni, K, Trichopoulou, A, Trichopoulos, D, Tzonou, A, Baltzell, KA, Dabancens, A, Martinez, L, Molina, R, Salas, O, Alexander, FE, Anderson, K, Folsom, AR, Gammon, MD, Hulka, BS, Millikan, R, Chilvers, CED, Lumachi, F, Bain, C, Schofield, F, Siskind, V, Rebbeck, TR, Bernstein, LR, Enger, S, Haile, RW, Paganini-Hill, A, Ross, RK, Ursin, G, Wu, AH, Yu, MC, Ewertz, DM, Clarke, EA, Bergkvist, L, Anderson, GL, Gass, M, O'Sullivan, MJ, Kalache, A, Farley, TMM, Holck, S, Meirik, O, Fukao, A, Factors, CGH, Grp, SHNHSIIIR, Epidemiologie, RS: CAPHRI School for Public Health and Primary Care, RS: GROW - School for Oncology and Reproduction, RS: GROW - R1 - Prevention, RS: CAPHRI - R5 - Optimising Patient Care, and Collaborative Group on Hormonal Factors in Breast Cancer

Subjects
Aging, Breast cancer, Risk factors, Menopause, Menarche, cancer, malignancy, Ethnic origin, Disease, 0302 clinical medicine, Breast cancer, Risk Factors, Neoplasms, Receptors, Epidemiology, 80 and over, 030212 general & internal medicine, skin and connective tissue diseases, Aged, 80 and over, Patient, Obstetrics, Reproduction, Smoking, Age Factors, Middle Aged, Reproducibility, 3. Good health, Menopause, Receptors, Estrogen, Oncology, 030220 oncology & carcinogenesis, Menarche, Hormonal therapy, Female, epidemiology, Cancer Type - Breast Cancer, history, Adult, Risk, trends, medicine.medical_specialty, Design, Neoplasms, Hormone-Dependent, Requiring prolonged observation, Hormone Replacement Therapy, Oncology and Carcinogenesis, Breast Neoplasms, and over, Validity, methods, 03 medical and health sciences, Age, Clinical Research, Breast Cancer, medicine, Humans, cancer, Neoplasm Invasiveness, Women, Oncology & Carcinogenesis, Hormone-Dependent, breast, Aged, Gynecology, Collaborative Group on Hormonal Factors in Breast Cancer, therapy, business.industry, Contraception/Reproduction, Research, Estrogens, Etiology - Resources and Infrastructure, medicine.disease, Estrogen, Good Health and Well Being, cessation, Premenopause, Risk factors, Relative risk, Recall, business, malignancy, Meta-Analysis
Abstract

Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity associated with reproduction, and affect breast cancer risk. Our aim was to assess the strengths of their effects and determine whether they depend on characteristics of the tumours or the affected women.Methods Individual data from 117 epidemiological studies, including 118 964 women with invasive breast cancer and 306 091 without the disease, none of whom had used menopausal hormone therapy, were included in the analyses. We calculated adjusted relative risks (RRs) associated with menarche and menopause for breast cancer overall, and by tumour histology and by oestrogen receptor expression.Findings Breast cancer risk increased by a factor of 1.050 (95% CI 1.044-1.057; p < 0.0001) for every year younger at menarche, and independently by a smaller amount (1.029, 1.025-1.032; p < 0.0001), for every year older at menopause. Premenopausal women had a greater risk of breast cancer than postmenopausal women of an identical age (RR at age 45-54 years 1.43, 1.33-1.52, p < 0.001). All three of these associations were attenuated by increasing adiposity among postmenopausal women, but did not vary materially by women's year of birth, ethnic origin, childbearing history, smoking, alcohol consumption, or hormonal contraceptive use. All three associations were stronger for lobular than for ductal tumours (p < 0.006 for each comparison). The effect of menopause in women of an identical age and trends by age at menopause were stronger for oestrogen receptor-positive disease than for oestrogen receptor-negative disease (p < 0.01 for both comparisons).Interpretation The effects of menarche and menopause on breast cancer risk might not be acting merely by lengthening women's total number of reproductive years. Endogenous ovarian hormones are more relevant for oestrogen receptor-positive disease than for oestrogen receptor-negative disease and for lobular than for ductal tumours.Funding Cancer Research UK.

Published
2012
Full Text
View/download PDF

44. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies

Author

Beral, V. Bull, D. Pirie, K. Reeves, G. Peto, R. and Skegg, D. LaVecchia, C. Magnusson, C. Pike, M. C. and Thomas, D. Hamajima, N. Hirose, K. Tajima, K. Rohan, T. and Friedenreich, C. M. Calle, E. E. Gapstur, S. M. Patel, A. V. Coates, R. J. Liff, J. M. Talamini, R. and Chantarakul, N. Koetsawang, S. Rachawat, D. Marcou, Y. and Kakouri, E. Duffy, S. W. Morabia, A. Schuman, L. and Stewart, W. Szklo, M. Coogan, P. F. Palmer, J. R. and Rosenberg, L. Band, P. Coldman, A. J. Gallagher, R. P. and Hislop, T. G. Yang, P. Cummings, S. R. Canfell, K. and Sitas, F. Chao, P. Lissowska, J. Horn-Ross, P. L. John, E. M. Kolonel, L. M. Nomura, A. M. Y. Ghiasvand, R. Hu, J. Johnson, K. C. Mao, Y. Callaghan, K. Crossley, B. and Goodill, A. Green, J. Hermon, C. Key, T. Lindgard, I. and Liu, B. Collins, R. Doll, R. Bishop, T. Fentiman, I. S. De Sanjose, S. Gonzaler, C. A. Lee, N. Marchbanks, P. and Ory, H. W. Peterson, H. B. Wingo, P. Ebeling, K. and Kunde, D. Nishan, P. Hopper, J. L. Eliassen, H. and Gajalakshmi, V. Martin, N. Pardthaisong, T. Silpisornkosol, S. Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. Wongsrichanalai, C. Neugut, A. and Santella, R. Baines, C. J. Kreiger, N. Miller, A. B. and Wall, C. Tjonneland, A. Jorgensen, T. Stahlberg, C. and Pedersen, A. Tonnes Flesch-Janys, D. Hakansson, N. Cauley, J. Heuch, I. Adami, H. O. Persson, I. Weiderpass, E. and Chang-Claude, J. Kaaks, R. McCredie, M. Paul, C. Spears, G. F. S. Iwasaki, M. Tsugane, S. Anderson, G. Daling, J. R. Hampton, J. Hutchinson, W. B. Li, C. I. Malone, K. and Mandelson, M. Newcomb, P. Noonan, E. A. Ray, R. M. and Stanford, J. L. Tang, M. T. C. Weiss, N. S. White, E. and Izquierdo, A. Viladiu, P. Fourkala, E. O. Jacobs, I. and Menon, U. Ryan, A. Cuevas, H. R. Ontiveros, P. Palet, A. and Salazar, S. B. Aristizabal, N. Cuadros, A. and Tryggvadottir, L. Tulinius, H. Riboli, E. Andrieu, N. and Bachelot, A. Le, M. G. Bremond, A. Gairard, B. Lansac, J. Piana, L. Renaud, R. Clavel-Chapelon, F. Fournier, A. and Touillaud, M. Mesrine, S. Chabbert-Buffet, N. and Boutron-Ruault, M. C. Wolk, A. Torres-Mejia, G. Franceschi, S. Romieu, I. Boyle, P. Lubin, F. Modan, B. Ron, E. and Wax, Y. Friedman, G. D. Hiatt, R. A. Levi, F. and Kosmelj, K. Primic-Zakelj, M. Ravnihar, B. Stare, J. and Ekbom, A. Erlandsson, G. Beeson, W. L. Fraser, G. Peto, J. Hanson, R. L. Leske, M. C. Mahoney, M. C. Nasca, P. C. Varma, A. O. Weinstein, A. L. Hartman, M. L. Olsson, H. Goldbohm, R. A. van den Brandt, P. A. Palli, D. and Teitelbaum, S. Apelo, R. A. Baens, J. de la Cruz, J. R. and Javier, B. Lacaya, L. B. Ngelangel, C. A. La Vecchia, C. and Negri, E. Marubini, E. Ferraroni, M. Gerber, M. and Richardson, S. Segala, C. Gatei, D. Kenya, P. Kungu, A. and Mati, J. G. Brinton, L. A. Freedman, M. Hoover, R. and Schairer, C. Ziegler, R. Banks, E. Spirtas, R. Lee, H. P. Rookus, M. A. van Leeuwen, F. E. Schoenberg, J. A. and Graff-Iversen, S. Selmer, R. Jones, L. McPherson, K. and Neil, A. Vessey, M. Yeates, D. Mabuchi, K. Preston, D. and Hannaford, P. Kay, C. McCann, S. E. Rosero-Bixby, L. and Gao, Y. T. Jin, F. Yuan, J-M Wei, H. Y. Yun, T. and Zhiheng, C. Berry, G. Booth, J. Cooper Jelihovsky, T. and MacLennan, R. Shearman, R. Hadjisavvas, A. Kyriacou, K. and Loisidou, M. Zhou, X. Wang, Q-S Kawai, M. Minami, Y. and Tsuji, I. Lund, E. Kumle, M. Stalsberg, H. Shu, X. O. and Zheng, W. Monninkhof, E. M. Onland-Moret, N. C. Peeters, P. H. M. Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. and Tzonou, A. Baltzell, K. A. Dabancens, A. Martinez, L. and Molina, R. Salas, O. Alexander, F. E. Anderson, K. and Folsom, A. R. Gammon, M. D. Hulka, B. S. Millikan, R. and Chilvers, C. E. D. Lumachi, F. Bain, C. Schofield, F. and Siskind, V. Rebbeck, T. R. Bernstein, L. R. Enger, S. and Haile, R. W. Paganini-Hill, A. Ross, R. K. Ursin, G. Wu, A. H. Yu, M. C. Ewertz, Denmark M. Clarke, E. A. and Bergkvist, L. Gass, M. O'Sullivan, M. J. Kalache, A. and Farley, T. M. M. Holck, S. Meirik, O. Fukao, A. and Collaborative Grp Hormonal Factors Collaborative Grp Hormonal Factors S Hankinson Nurses Hlth Study I II

Subjects
skin and connective tissue diseases
Abstract

Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity associated with reproduction, and affect breast cancer risk. Our aim was to assess the strengths of their effects and determine whether they depend on characteristics of the tumours or the affected women. Methods Individual data from 117 epidemiological studies, including 118 964 women with invasive breast cancer and 306 091 without the disease, none of whom had used menopausal hormone therapy, were included in the analyses. We calculated adjusted relative risks (RRs) associated with menarche and menopause for breast cancer overall, and by tumour histology and by oestrogen receptor expression. Findings Breast cancer risk increased by a factor of 1.050 (95% CI 1.044-1.057; p < 0.0001) for every year younger at menarche, and independently by a smaller amount (1.029, 1.025-1.032; p < 0.0001), for every year older at menopause. Premenopausal women had a greater risk of breast cancer than postmenopausal women of an identical age (RR at age 45-54 years 1.43, 1.33-1.52, p < 0.001). All three of these associations were attenuated by increasing adiposity among postmenopausal women, but did not vary materially by women’s year of birth, ethnic origin, childbearing history, smoking, alcohol consumption, or hormonal contraceptive use. All three associations were stronger for lobular than for ductal tumours (p < 0.006 for each comparison). The effect of menopause in women of an identical age and trends by age at menopause were stronger for oestrogen receptor-positive disease than for oestrogen receptor-negative disease (p < 0.01 for both comparisons). Interpretation The effects of menarche and menopause on breast cancer risk might not be acting merely by lengthening women’s total number of reproductive years. Endogenous ovarian hormones are more relevant for oestrogen receptor-positive disease than for oestrogen receptor-negative disease and for lobular than for ductal tumours. Funding Cancer Research UK.

Published
2012

45. Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies

Author

Beral, V. Gaitskell, K. Hermon, C. Moser, K. Reeves, G. and Peto, R. Brinton, L. Marchbanks, P. Negri, E. Ness, R. Peeters, P. H. M. Vessey, M. Calle, E. E. Gapstur, S. M. Patel, A. V. Dal Maso, L. Talamini, R. Chetrit, A. and Hirsh-Yechezkel, G. Lubin, F. Sadetzki, S. Banks, E. and Bull, D. Callaghan, K. Crossley, B. Goodill, A. Green, J. Key, T. Sitas, F. Collins, R. Doll, R. Gonzalez, A. Lee, N. Ory, H. W. Peterson, H. B. Wingo, P. A. and Martin, N. Pardthaisong, T. Silpisornkosol, S. Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. Wongsrichanalai, C. Tjonneland, A. Titus-Ernstoff, L. and Byers, T. Rohan, T. Mosgaard, B. J. Yeates, D. and Freudenheim, J. L. Chang-Claude, J. Kaaks, R. Anderson, K. E. Folsom, A. Robien, K. Hampton, J. Newcomb, P. A. and Rossing, M. A. Thomas, D. B. Weiss, N. S. Riboli, E. and Clavel-Chapelon, F. Cramer, D. Hankinson, S. E. Tworoger, S. S. Franceschi, S. La Vecchia, C. Adami, H. O. Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. Schouten, L. J. and van den Brandt, P. A. Chantarakul, N. Koetsawang, S. and Rachawat, D. Palli, D. Black, A. Freedman, D. M. Hartge, P. Hsing, A. W. Lacey, Jr., J. V. Hoover, R. N. and Schairer, C. Urban, M. Graff-Iversen, S. Selmer, R. and Bain, C. J. Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. Moysich, K. McCann, S. E. Hannaford, P. Kay, C. and Binns, C. W. Lee, A. H. Zhang, M. Nasca, P. Coogan, P. F. Palmer, J. R. Rosenberg, L. Kelsey, J. and Paffenbarger, R. Whittemore, A. Katsouyanni, K. and Trichopoulou, A. Trichopoulos, D. Tzonou, A. Dabancens, A. and Martinez, L. Molina, R. Salas, O. Goodman, M. T. and Lurie, G. Carney, M. E. Wilkens, L. R. Hartman, L. and Manjer, J. Olsson, H. Grisso, J. A. Morgan, M. Wheeler, J. E. Bunker, C. H. Edwards, R. P. Modugno, F. and Casagrande, J. Pike, M. C. Ross, R. K. Wu, A. H. Miller, A. B. Kumle, M. Gram, I. T. Lund, E. McGowan, L. and Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. Risch, H. A. Collaborative Grp Epidemiological Natl Israeli Study Ovarian Canc Nurses Hlth Study

Abstract

Background Smoking has been linked to mucinous ovarian cancer, but its effects on other ovarian cancer subtypes and on overall ovarian cancer risk are unclear, and the findings from most studies with relevant data are unpublished. To assess these associations, we review the published and unpublished evidence. Methods Eligible epidemiological studies were identified by electronic searches, review articles, and discussions with colleagues. Individual participant data for 28 114 women with and 94 942 without ovarian cancer from 51 epidemiological studies were analysed centrally, yielding adjusted relative risks (RRs) of ovarian cancer in smokers compared with never smokers. Findings After exclusion of studies with hospital controls, in which smoking could have affected recruitment, overall ovarian cancer incidence was only slightly increased in current smokers compared with women who had never smoked (RR 1.06, 95% CI 1.01-1.11, p=0.01). Of 17 641 epithelial cancers with specified histology, 2314 (13%) were mucinous, 2360 (13%) endometrioid, 969 (5%) clear-cell, and 9086 (52%) serous. Smoking-related risks varied substantially across these subtypes (p(heterogeneity)

Published
2012

46. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies

Author

Hamajima, N, Hirose, K, Tajima, K, Rohan, T, Friedenreich, CM, Calle, EE, Gapstur, SM, Patel, AV, Coates, RJ, Liff, JM, Talamini, R, Chantarakul, N, Koetsawang, S, Rachawat, D, Marcou, Y, Kakouri, E, Duffy, SW, Morabia, A, Schuman, L, Stewart, W, Szklo, M, Coogan, PF, Palmer, JR, Rosenberg, L, Band, P, Coldman, AJ, Gallagher, RP, Hislop, TG, Yang, P, Cummings, SR, Canfell, K, Sitas, F, Chao, P, Lissowska, J, Horn-Ross, PL, John, EM, Kolonel, LM, Nomura, AMY, Ghiasvand, R, Hu, J, Johnson, KC, Mao, Y, Beral, V, Bull, D, Callaghan, K, Crossley, B, Goodill, A, Green, J, Hermon, C, Key, T, Lindgard, I, Liu, B, Pirie, K, Reeves, G, Collins, R, Doll, R, Peto, R, Bishop, T, Fentiman, IS, De Sanjosé, S, Gonzalez, CA, Lee, N, Marchbanks, P, Ory, HW, Peterson, HB, Wingo, P, Ebeling, K, Kunde, D, Nishan, P, Hopper, JL, Eliassen, H, Hankinson, S, Gajalakshmi, V, Martin, N, Pardthaisong, T, Silpisornkosol, S, Theetranont, C, Boosiri, B, Chutivongse, S, Jimakorn, P, Virutamasen, P, Wongsrichanalai, C, Neugut, A, Santella, R, Baines, CJ, Kreiger, N, Miller, AB, Wall, C, Tjonneland, A, Jorgensen, T, Stahlberg, C, Pedersen, AT, Flesch-Janys, D, Hakansson, N, Cauley, J, Heuch, I, Adami, HO, Persson, I, Weiderpass, E, and Magnusson, C

Subjects
skin and connective tissue diseases
Abstract

Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity associated with reproduction, and affect breast cancer risk. Our aim was to assess the strengths of their effects and determine whether they depend on characteristics of the tumours or the affected women. Methods Individual data from 117 epidemiological studies, including 118 964 women with invasive breast cancer and 306 091 without the disease, none of whom had used menopausal hormone therapy, were included in the analyses. We calculated adjusted relative risks (RRs) associated with menarche and menopause for breast cancer overall, and by tumour histology and by oestrogen receptor expression. Findings Breast cancer risk increased by a factor of 1.050 (95% CI 1.044-1.057; p

Published
2012
Full Text
View/download PDF

47. Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

Author

Beral, V. Hermon, C. Peto, R. Reeves, G. Brinton, L. and Marchbanks, P. Negri, E. Ness, R. Peeters, P. H. M. and Vessey, M. Calle, E. E. Gapstur, S. M. Patel, A. V. Dal Maso, L. Talamini, R. Chetrit, A. Hirsh-Yechezkel, G. and Lubin, F. Sadetzki, S. Allen, N. Bull, D. Callaghan, K. and Crossley, B. Gaitskell, K. Goodill, A. Green, J. and Key, T. Moser, K. Collins, R. Doll, R. Gonzalez, C. A. and Lee, N. Ory, H. W. Peterson, H. B. Wingo, P. A. and Martin, N. Pardthaisong, T. Silpisornkosol, S. Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. Wongsrichanalai, C. Tjonneland, A. Titus-Ernstoff, L. and Byers, T. Rohan, T. Mosgaard, B. J. Yeates, D. and Freudenheim, J. L. Chang-Claude, J. Kaaks, R. Anderson, K. E. Folsom, A. Robien, K. Rossing, M. A. Thomas, D. B. and Weiss, N. S. Riboli, E. Clavel-Chapelon, F. Cramer, D. and Hankinson, S. E. Tworoger, S. S. Franceschi, S. La Vecchia, C. Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. Schouten, L. J. van den Brandt, P. A. Chantarakul, N. and Koetsawang, S. Rachawat, D. Palli, D. Black, A. de Gonzalez, A. Berrington Freedman, D. M. Hartge, P. Hsing, A. W. Lacey, Jr., J. V. Hoover, R. N. Schairer, C. and Graff-Iversen, S. Selmer, R. Bain, C. J. Green, A. C. and Purdie, D. M. Siskind, V. Webb, P. M. McCann, S. E. and Hannaford, P. Kay, C. Binns, C. W. Lee, A. H. Zhang, M. and Ness, R. B. Nasca, P. Coogan, P. F. Palmer, J. R. and Rosenberg, L. Kelsey, J. Paffenbarger, R. Whittemore, A. and Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. Tzonou, A. and Dabancens, A. Martinez, L. Molina, R. Salas, O. and Goodman, M. T. Lurie, G. Carney, M. E. Wilkens, L. R. and Hartman, L. Manjer, J. Olsson, H. Grisso, J. A. Morgan, M. Wheeler, J. E. Casagrande, J. Pike, M. C. Ross, R. K. and Wu, A. H. Miller, A. B. Kumle, M. Lund, E. McGowan, L. Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. and Meirik, O. Risch, H. A. Collaborative Grp Epidemiol Studie

Abstract

Background: Only about half the studies that have collected information on the relevance of women’s height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p

Published
2012

50. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

Author

Beral, V. Doll, R. Hermon, C. Peto, R. Reeves, G. and Brinton, L. Green, A. C. Marchbanks, P. Negri, E. Ness, R. Peeters, P. Vessey, M. Calle, E. E. Rodriguez, C. and Dal Maso, L. Talamini, R. Cramer, D. Hankinson, S. E. and Tworoger, S. S. Chetrit, A. Hirsh-Yechezkel, G. Lubin, F. and Sadetzki, S. Appleby, P. Banks, E. de Gonzalez, A. Berrington Bull, D. Crossley, B. Goodil, A. Green, I. and Green, J. Key, T. Collins, R. Gonzalez, C. A. Lee, N. Ory, H. W. Peterson, H. B. Wingo, P. A. Martin, N. and Pardthaisong, T. Silpisornkosol, S. Theetranont, C. and Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. and Wongsrichanalai, C. Titus-Ernstoff, L. Mosgaard, M. J. and Yeates, D. Chang-Claude, J. Rossing, M. A. Thomas, D. and Weiss, N. Franceschi, S. La Vecchia, C. Adami, H. O. and Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. Brinton, L. A. Freedman, D. M. Hartge, P. Lacey, J. M. Hoover, R. and Schouten, L. J. van den Brandt, P. A. Chantarakul, N. and Koetsawang, S. Rachawat, D. Graff-Iversen, S. Selmer, R. and Bain, C. J. Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. McCann, S. E. Hannaford, P. Kay, C. Binns, C. W. and Lee, A. H. Zhang, M. Nasca, P. Coogan, P. F. Kelsey, J. Paffenbarger, R. Whittemore, A. Katsouyanni, K. and Trichopoulou, A. Trichopoulos, D. Tzonou, A. Dabancens, A. and Martinez, L. Molina, R. Salas, O. Goodman, M. T. and Laurie, G. Carney, M. E. Wilkens, L. R. Bladstrom, A. and Olsson, H. Ness, R. B. Grisso, J. A. Morgan, M. Wheeler, J. E. Peeters, P. Casagrande, J. Pike, M. C. Ross, R. K. and Wu, A. H. Kumle, M. Lund, E. McGowan, L. Shu, X. O. and Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. and Risch, H. A. Collaborative Grp Epidemiological

Abstract

Background Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Methods Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy. Findings Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations among users of 4 . 4 and 5 . 0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian cancer risk (p

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results